7-alkoxy-4-phenylamino-3-quinolinecarbonitriles as dual inhibitors of Src and Abl kinases

被引：70

作者：

Boschelli, DH ^{[1
]}

Wang, YND ^{[1
]}

Johnson, S ^{[1
]}

Wu, BQ ^{[1
]}

Ye, F ^{[1
]}

Sosa, ACB ^{[1
]}

Golas, JM ^{[1
]}

Boschelli, F ^{[1
]}

机构：

[1] Wyeth Ayerst Res, Pearl River, NY 10965 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2004年 / 47卷 / 07期

关键词：

D O I：

10.1021/jm0499458

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We previously reported that several 7-alkoxy-4-phenylamino-3-quinolinecarbonitriles were potent inhibitors of Src kinase activity. We disclose here a new highly efficient and versatile route to these compounds, which are also potent inhibitors of Abl kinase.

引用

页码：1599 / 1601

页数：3

共 33 条

[1] Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity
Boschelli, DH
Ye, F
Wang, YD
Dutia, M
Johnson, SL
Wu, BQ
Miller, K
Powell, DW
Yaczko, D
Young, M
Tischler, M
Arndt, K
Discafani, C
Etienne, C
Gibbons, J
Grod, J
Lucas, J
Weber, JM
Boschelli, F
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (23) : 3965 - 3977
[2] Investigation of the effect of varying the 4-anilino and 7-alkoxy groups of 3-quinolinecarbonitriles on the inhibition of Src kinase activity
Boschelli, DH
Fe, Y
Wu, BQ
Wang, YD
Sosa, ACB
Yaczko, D
Powell, D
Golas, JM
Lucas, J
Boschelli, F
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (21) : 3797 - 3800
[3] Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug
Capdeville, R
Buchdunger, E
Zimmermann, J
Matter, A
[J]. NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (07) : 493 - 502
[4] Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571
Corbin, AS
Buchdunger, E
Pascal, F
Druker, BJ
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (35) : 32214 - 32219
[5] Role of Src in signal transduction pathways
Courtneidge, SA
[J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2002, 30 : 11 - 17
[6] Dorsey JF, 2000, CANCER RES, V60, P3127
[7] Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
Druker, BJ
Lydon, NB
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (01) : 3 - 7
[8] Src in cancer: deregulation and consequences for cell behaviour
Frame, MC
[J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2002, 1602 (02): : 114 - 130
[9] Golas JM, 2003, CANCER RES, V63, P375
[10] Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
Gorre, ME
Mohammed, M
Ellwood, K
Hsu, N
Paquette, R
Rao, PN
Sawyers, CL
[J]. SCIENCE, 2001, 293 (5531) : 876 - 880

← 1 2 3 4 →